单次大剂量率近距离放疗联合局灶剂量递增治疗前列腺癌的2期临床试验成熟结果
本2期试验纳入50例局限性前列腺腺癌患者,接受单次HDR-BT,DIL处方21 Gy,其余前列腺采用两种递减方案。中位随访70.6个月,5年bNED在轻度递减组为88%、中度递减组为76%(p=0.05),FFLF差异有统计学意义(p=0.03)。结论认为局灶boost未改善生化或局部控制。
要点
- 单次HDR-BT联合DIL局灶递增21 Gy,5年bNED轻度递减组88%、中度递减组76%。
- 4年和5年FFLF轻度递减组100%和96%,中度递减组92%和84%,差异有统计学意义(p=0.03)。
- 无急性≥G3泌尿或≥G2胃肠毒性报告,IIEF中位数前6个月下降后54个月回升至20。
核心结论
- 与全腺体单次19 Gy的预期相比,DIL局灶boost未改善单次HDR单药治疗后的生化或局部控制。
主要发现
- 中位随访70.6个月,15例出现生化失败,其中轻度递减组(组1)8例、中度递减组(组2)7例。
- 5年bNED组1为88%、组2为76%(p=0.05)。
- 4年和5年FFLF组1为100%和96%,组2为92%和84%,差异有统计学意义(p=0.03)。
- 未报告急性≥G3泌尿或≥G2胃肠毒性。
- IIEF中位数在前6个月下降,54个月时回升至峰值中位数20。
关键数值与推荐
- DIL处方剂量为21 Gy,其余前列腺采用两种递减处方方案。
- 主要结局包括bNED、LRFS和MFS,次要结局包括晚期泌尿、胃肠和性毒性。
临床怎么用
- 单次HDR-BT时对DIL进行21 Gy局灶递增并递减其余前列腺剂量,在本试验中未显示优于全腺体19 Gy单次的预期生化或局部控制。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIM: The dominant intraprostatic lesion (DIL) is the commonest site of relapse after single dose high-dose-rate brachytherapy (HDR-BT) for localised prostate cancer. This study investigated toxicity and clinical outcomes of focal dose escalation to the DIL with dose de-escalation to the remaining prostate. MATERIALS/METHODS: Between November 2012 and July 2016, 50 patients with localised prostate adenocarcinoma received single fraction HDR-BT. 21 Gy was prescribed to the DIL, with two de-escalation prescription schedules for the remaining prostate. Primary outcomes included biochemical no evidence of disease (bNED), local recurrence free survival (LRFS), and metastasis free survival (MFS). Secondary outcomes included late genitourinary, gastrointestinal and sexual toxicity. Kaplan-Meier analyses with log rank tests were used to estimate bNED, LRFS and MFS. RESULTS: With a median follow up of 70.6 months, 15 patients developed biochemical failure, including 8 in the group that received minor dose de-escalation to the non-DIL prostate (group 1) and 7 in the group that received moderate de-escalation (group 2). Five-year bNED was 88% in group 1 and 76% in group 2 (p = 0.05). Overall 4-year and 5-year FFLF in group 1 was 100% and 96% and in group 2 92% and 84%. These differences were statistically significant (p = 0.03). No acute ≥G3 genitourinary or ≥G2 gastrointestinal toxicity was reported. The median IIEF decreased in the first 6 months improving to a peak median score of 20 at 54 months. CONCLUSION: Focal boost to the DIL did not improve biochemical or local control after single-fraction HDR monotherapy compared to what would be expected from 19 Gy single fraction treatment to the whole gland.
引用
- Armstrong S, Brown S, Stancliffe M, et al. Single dose high-dose-rate brachytherapy with focal dose escalation for prostate cancer: Mature results of a phase 2 clinical trial. Radiother Oncol. 2021. PMID: 33766703. doi:10.1016/j.radonc.2021.03.018
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。